Biofrontera (BFRI) Stock Price, News & Analysis

Company Overview

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis. Ameluz is used in combination with the BF-RhodoLED® lamp, a medical device designed to emit the precise wavelength of red light required to activate the gel. This integrated pharmaceutical–device approach underpins the company’s position in the PDT market.

Founded in 1997 and headquartered in Leverkusen, Germany, Biofrontera maintains operations in multiple geographies, including a U.S. subsidiary established to support commercialization efforts in North America. Beyond its approved indications, the company is exploring additional dermatological uses for its photodynamic platform and is engaged in discussions with regulatory authorities and commercial partners to expand its presence in key markets such as Canada, Turkey and beyond.

Biofrontera’s management team brings together expertise in dermatology, pharmaceutical development and medical device manufacturing. The company continues to invest in its pipeline, seeking to leverage its PDT technology for new indications and to forge strategic partnerships that will broaden access to its therapies worldwide.

Key Stats

• Today's Range: $1.00 to $1.07
• 50-Day Range: $0.78 to $1.15
• 52-Week Range: $0.55 to $1.19
• Volume: 394,399 shs
• Average Volume: 257,774 shs
• Market Capitalization: $12.93 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Biofrontera Stock Analysis - MarketRank™

Biofrontera scored higher than 20% of companies evaluated by MarketBeat, and ranked 753rd out of 850 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.2 / 5
• Analyst Rating: Hold

Consensus Rating

Biofrontera has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Biofrontera has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Biofrontera are expected to grow in the coming year, from ($0.30) to $0.06 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Biofrontera is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Biofrontera is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Biofrontera has a P/B Ratio of 1.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.48% of the float of Biofrontera has been sold short.

Short Interest Ratio / Days to Cover

Biofrontera has a short interest ratio ("days to cover") of 0.28, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biofrontera has recently decreased by 19.15%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Biofrontera does not currently pay a dividend.

Dividend Growth

Biofrontera does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for BFRI on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Biofrontera insiders have not sold or bought any company stock.

Percentage Held by Insiders

8.10% of the stock of Biofrontera is held by insiders.

Percentage Held by Institutions

10.08% of the stock of Biofrontera is held by institutions.

Company Calendar

• Last Earnings: 5/14/2026
• Today: 7/06/2026
• Next Earnings (Estimated): 8/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BFRI
• CIK: 1858685
• Web: www.biofrontera-us.com
• Phone: 781-245-1325
• Fax: N/A
• Employees: 70
• Year Founded: 2012

Profitability

• EPS (Trailing Twelve Months): ($0.97)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$10.54 million
• Net Margins: -25.66%
• Pretax Margin: -25.60%
• Return on Equity: -515.34%
• Return on Assets: -53.91%

Debt

• Debt-to-Equity Ratio: 0.78
• Current Ratio: 1.20
• Quick Ratio: 1.09

Sales & Book Value

• Annual Sales: $41.71 million
• Price / Sales: 0.31
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.90 per share
• Price / Book: 1.12

Miscellaneous

• Outstanding Shares: 12,800,000
• Free Float: 11,766,000
• Market Cap: $12.93 million
• Optionable: No Data
• Beta: 0.81